Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Key Points Pfizer stands as one of the largest pharmaceutical companies in the world.Although it has an attractive 7.1% yield, it has a big blemish in its dividend past.Investors looking at drug ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer (PFE) stock in focus as Sally Susman, the company's Chief Corporate Affairs Officer, plans to depart after 18 years. Read more here.

Okay, well, I have not been recommending, my stock in the pharma business is Lilly, and the med equipment is Abbott. I do ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

The Bristol Myers Squibb-Pfizer Alliance today announced a new direct-to-patient option for purchasing Eliquis (apixaban) via ...

According to Bloomberg, citing an email sent by Chief Executive Officer Albert Bourla on Tuesday, Susman’s responsibilities will be divided among five executives at the company. The email described ...

The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by risi ...